Skip to main content
OpenTrials
Completed

NCT Number: NCT04054648

BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?

High blood pressure (present in 1 of 5 Canadian adults) increases the risk of heart attack and stroke. Blood pressure lowering pills reduce this risk - but perhaps not optimally. A Spanish study suggests that using blood pressure pills at bedtime, instead of in the morning (when they are most commonly used), reduces death, heart attack, and stroke by more than 50%. If true, a switch to bedtime prescribing would have more impact on the health of those with high blood pressure than whether high blood pressure is treated at all.

BedMed, a community-based Canadian primary care trial, is already running and looking both to validate the findings of this Spanish study and to determine whether there might be unrecognized harms of bedtime use (such as more falls and fractures as a result of lower overnight blood pressure). One very important population that is likely to be more sensitive to the effects of medications, and almost always excluded from randomized trials, are the frail elderly (such as those who are resident in nursing homes). In order to have the greatest information about the safety and effectiveness of bedtime blood pressure medications, the BedMed team is additionally conducting a similar trial to BedMed in nursing homes ("BedMed-Frail" - the subject of this trial registration) to determine whether the risks and benefits of bedtime prescribing differ in this highly understudied population.

Basics of the trial: When patients are admitted to nursing homes, neither they nor their physicians are consulted about the timing of blood pressure medication. Unless explicitly stated to be otherwise, blood pressure pills are instead largely arbitrarily assigned for morning use by default. Given there is evidence that bedtime administration may be safer, the nursing homes participating in BedMed-Frail will have each hypertensive resident randomized to either continue with morning blood pressure medication use, as is their norm, or to have their facility's pharmacist gradually switch each residents blood pressure pills to bedtime. Over a period of roughly 3 years, health outcomes in these facilities will be tracked using routinely collected electronic health data to determine differences in things like hospitalization, death, or hip fractures - and at the end of the study the investigators hope to determine whether or not the recommendations for blood pressure medication timing in frail older adults should differ from those for the general population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Dementia Femoral Fractures Fractures, Bone Heart Diseases Heart Failure Hip Fractures Hip Injuries Infarction Ischemia Leg Injuries Mental Disorders Myocardial Infarction Myocardial Ischemia Necrosis Nervous System Diseases Neurocognitive Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Stroke Vascular Diseases Wounds and Injuries

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Multiple Alberta Long Term Care Facilities

Edmonton, Alberta, Canada

About this study

The BedMed trial (led out of the University of Alberta and funded by both Alberta Innovates Health Solutions, and the Canadian Institutes for Health Research) is a pragmatic multi-provincial trial intended to determine whether bedtime antihypertensive use, as compared to conventional morning use, reduces major adverse cardiovascular events in community dwelling primary care patients.

BedMed-Frail, led by the same group of investigators, is a complementary but separate randomized trial evaluating whether the risks and benefits of bedtime antihypertensive use differ in a long-term care (LTC) population. To accomplish this, within participating Alberta LTC and supportive living facilities, eligible residents with hypertension will be randomized at the patient level to the antihypertensive medication timing intervention (i.e. bedtime versus continued morning use). Trial outcomes and baseline characteristics are drawn from routinely collected electronic health data - using both provincial administrative health claims data and the Resident Assessment Instrument Minimum Data Set (RAI-MDS), which is a standard instrument for collecting clinical information in Canadian LTC facilities.

BedMed-Frail is event driven, receiving quarterly reporting of total events from the Alberta Support for Patient Oriented Research (SPOR) Unit's Data Platform. Funding permitting, the trial will continue until observation of 368 primary outcome events. Upon observation of half that number, an independent data safety monitoring board (IDSMB) chaired by Dr. James Wright (Cochrane Hypertension Review Group Co-ordinating Editor) will examine all available outcomes. If p is ≤ 0.001 for benefit (the Haybittle-Peto boundary - recommended to reduce the chance of stopping too early and magnifying benefit), or if p is ≤ 0.05 for harm, the IDSMB will apply clinical judgement and make recommendations to the steering committee on whether the trial should break early.

The outcomes of BedMed-Frail are primarily designed to be analogous to the cardiovascular and safety outcomes monitored for in the community BedMed study. However BedMed-Frail is also examining for differences in behaviour issues between groups. Both behavioural problems, and blood pressure, have circadian rhythms. Blood pressure is normally lower overnight and behavioural problems in long term care residents typically worsen during the same period - a phenomenon known as "sundowning". Conceivably, there could be a relationship between the two such that behaviour problems might improve, or worsen, with bedtime antihypertensive use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertension diagnosis as indicated by ≥ 2 such billing diagnoses at any time in the administrative claims data by any provider
  • ≥ 1 once daily BP lowering medication
  • Resident in a participating long term care facility.

Exclusion criteria

  • Personal history of glaucoma or use of glaucoma medications. Glaucoma is an exclusion because nocturnal hypotension (i.e. excessively low blood pressure while sleeping) has been associated with ischemic optic neuropathy in such patients.
  • Any patient / family member or treating physician (all of whom will be notified in advance of the LTC facilities participation in this initiative) requesting the patient not participate.

Treatment and study plan

Bedtime administration of the participant's pre-existing antihypertensive medications

Other

Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.

Primary outcomes

  1. Composite of Major Adverse Cardiovascular Events

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Composite of all-cause death and hospital admission or emergency room visit for acute coronary syndrome / myocardial infarction, heart failure, or stroke - as recorded in governmental health claims databases

Secondary outcomes

  1. All Cause Mortality

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    All cause death - as recorded in governmental health claims databases

  2. Hospitalization for Acute Coronary Syndrome / Myocardial Infarction

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Hospitalization or emergency room visit for acute coronary syndrome / myocardial infarction - as recorded in governmental health claims databases

  3. Hospitalization for Stroke

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Hospitalization or emergency room visit for stroke - as recorded in governmental health claims databases

  4. Hospitalization for Congestive Heart Failure

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Hospitalization or emergency room visit for congestive heart failure - as recorded in governmental health claims databases

  5. All Cause Unplanned Hospitalization

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    All cause hospitalization or emergency room visit excluding elective surgeries or booked procedures / planned follow-up care - as recorded in governmental health claims databases

  6. Non-vertebral Fracture

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Any physician billing (hospital or community) for a fracture other than a vertebral fracture (which might indicate a vertebral compression fracture secondary to osteoporosis, and not trauma)

  7. Number of Patients with a Fall in the Last 30 days

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization

  8. Number of Patients with "Deteriorated Cognition Relative to Status 90 Days Prior"

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization

  9. Number of Patients with Urinary Incontinence

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Includes "occasionally incontinent" or more frequent, which equates to 2 or more episodes per week.

  10. Number of Patients with Partial or Full Thickness Decubitus Skin Ulceration ("Bed Sores")

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Requires some degree of skin breakdown and not just erythema (i.e. stages 2 to 4).

  11. Acute Care Costs

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Calculated from all hospitalizations using the resource intensity weight (RIW) and length of stay (LOS) as recorded in governmental health claims data

  12. Total Cost of Care

    Time frame: 3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)

    Acute care costs + medication costs + physician billings + nursing / facility costs as recorded in governmental health claims data. Nursing / facility costs will be estimated from level of care and duration of stay

Other outcomes

  1. Number of Participants with "Behavioural Symptoms that are Present a Minimum of 4 Days per Week and Not Easily Altered" Including a) Wandering, b) Verbal Abuse, c) Physical Abuse, d) Socially Inappropriate or Disruptive Behaviour, or e) Resisting Care

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization

  2. Number of Participants with Receipt (last 7 days) of Antipsychotic Medication or Physical Restraints

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Physical restraints include trunk restraints, limb restraints, or a chair that prevents rising, but does not include bedrails.

  3. Receipt of Anti-Anxiety Medication on 3 or more of the Last 7 Days

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization

  4. Receipt of a Bedtime Sleeping Pill on 3 or More of the Last 7 Days

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization

  5. Number of Participants Indicated by Nursing to Have at Least One "Indicator of Depression or Anxiety" Almost Daily in the Last 30 Days

    Time frame: 4.5 Months (Average - will occur within a 3 to 6 month post randomization window)

    As recorded by a nurse in the First Quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Applies to 16 discrete mood and anxiety related observations of the resident, any one of which being listed as present 6 or more days per week would qualify

  6. Proportion of BP Medication Doses Taken at Bedtime (Process Outcome)

    Time frame: Through study duration, up to 3 years, broken down monthly

    Obtained from the "directions for use" field in Pharmaceutical Information Network (PIN) data. For this calculation, medications dosed more than once a day are considered as 1/2 dose in the AM and 1/2 dose in the PM

  7. Use of at Least One Once Daily BP Medication at Bedtime (Process Outcome)

    Time frame: Through study duration, up to 3 years, broken down monthly

    Obtained from the "directions for use" field in Pharmaceutical Information Network (PIN) data.

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Collaborators

  • Alberta Health services
  • Alberta Innovates Health Solutions
  • Canadian Institutes of Health Research (CIHR)
  • EnACt

Registry information

Official study title

Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations? The "BedMed-Frail" Randomized Controlled Trial

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Aug 13, 2019
Registry last updated
Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.